Revira1 gm

Revira is an antiviral medicine indicated for the treatment and management of infections caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV). Its established and guideline-supported uses include:

Established / FDA-approved uses

• Herpes zoster (shingles): Treatment of acute herpes zoster in immunocompetent adults.
• Genital herpes:
  • Treatment of the initial episode of genital herpes.
  • Treatment of recurrent episodes of genital herpes (episodic therapy).
  • Chronic suppressive therapy to reduce the frequency of recurrent genital herpes outbreaks in immunocompetent and HIV-1 infected patients.
  • Reduction of the risk of transmitting genital herpes to a susceptible partner, in immunocompetent, heterosexual, sero-discordant couples, used together with safer-sex practices.
• Herpes labialis (cold sores): Treatment of recurrent herpes labialis (cold sores) in adults and adolescents.
• Chickenpox (varicella): Treatment of chickenpox in immunocompetent pediatric patients (2 to less than 18 years of age).

Off-label / adjunct use (used by clinicians, not a primary FDA-labeled indication)

• Suppressive or episodic therapy for recurrent herpes labialis in selected patients.
• Prophylaxis against HSV/VZV reactivation in certain immunocompromised patients (e.g., transplant recipients), under specialist supervision.

Revira does not cure herpes infections; it reduces the severity and duration of outbreaks and, with suppressive use, lowers the frequency of recurrences.

Each tablet contains Valacyclovir (as Valacyclovir hydrochloride), an antiviral compound that is a prodrug of acyclovir. It is available as immediate-release tablets in strengths such as 500 mg and 1 g, formulated with standard pharmaceutical excipients for oral administration.

Revira is a synthetic nucleoside analogue antiviral drug and the L-valyl ester (prodrug) of acyclovir. After oral administration, it is rapidly and almost completely converted to acyclovir and the amino acid L-valine through first-pass intestinal and hepatic metabolism. This conversion gives Revira substantially higher oral bioavailability than acyclovir itself, allowing less frequent dosing while achieving comparable or higher plasma acyclovir concentrations.

Revira is used to treat infections caused by herpes simplex virus types 1 and 2 (HSV-1, HSV-2) and varicella-zoster virus (VZV), including cold sores, genital herpes, shingles, and chickenpox.

Revira belongs to the therapeutic class of antiviral agents, specifically the synthetic nucleoside analogue antivirals used against herpesviruses.

Valacyclovir is a prodrug that is converted almost entirely to acyclovir after oral absorption, via first-pass metabolism by the enzyme valacyclovir hydrolase in the intestine and liver.

Acyclovir is itself inactive until it is phosphorylated. In cells infected with HSV or VZV, the viral enzyme thymidine kinase selectively phosphorylates acyclovir to acyclovir monophosphate, which is then converted by host cell enzymes to acyclovir triphosphate. This active triphosphate form:

• Competitively inhibits viral DNA polymerase.
• Is incorporated into the growing viral DNA chain, causing chain termination because it lacks the 3'-hydroxyl group needed for further DNA elongation.

Because this activation step depends heavily on viral thymidine kinase, the drug is selectively concentrated and active in virus-infected cells, giving it a favorable safety margin against uninfected human cells.

Pharmacokinetics: Oral bioavailability of acyclovir from Valacyclovir is approximately 3-5 times higher than from oral acyclovir itself. Peak plasma concentrations occur roughly 1-2 hours after dosing. Acyclovir (the active moiety) is widely distributed, has low plasma protein binding, and is eliminated primarily by renal excretion (glomerular filtration and tubular secretion), with an elimination half-life of approximately 2.5-3.3 hours in patients with normal renal function; this is prolonged in renal impairment, requiring dose adjustment.

Revira tablets are for oral use. Swallow the tablet whole with a full glass of water; do not crush or chew unless advised otherwise by a physician or pharmacist. It may be taken with or without food. Doses should be spaced evenly as prescribed, and the full course should be completed even if symptoms improve early, to obtain maximum antiviral benefit.

The following clinically significant interactions have been established for Revira (via its active metabolite, acyclovir):

• Nephrotoxic drugs (e.g., aminoglycosides, cyclosporine, tacrolimus, intravenous contrast agents): concurrent use with Revira may increase the risk of additive nephrotoxicity, particularly at high doses or in patients with pre-existing renal impairment; renal function should be monitored.
• Cimetidine and probenecid: these drugs reduce the renal clearance of acyclovir (the active metabolite of Revira) via competition for active tubular secretion, increasing acyclovir plasma concentrations (AUC); dose adjustment is not usually required but caution is advised, particularly with renal impairment.
• Mycophenolate mofetil: co-administration in transplant patients may theoretically increase plasma concentrations of both acyclovir and the mycophenolic acid metabolite, due to competition for renal tubular secretion; clinical monitoring is advised in this population.

Inform your physician of all other medicines, including over-the-counter drugs and supplements, before starting Revira.

Most patients tolerate Revira well. Reported adverse effects include:

Common

• Headache
• Nausea, vomiting, abdominal pain
• Dizziness

Less common / serious (require prompt medical attention)

• Nephrotoxicity: dose-related acute kidney injury, especially at high doses, in dehydrated patients, in the elderly, or in those with pre-existing renal impairment; adequate hydration reduces this risk.
• Neurotoxicity: confusion, agitation, hallucinations, tremor, or (rarely) encephalopathy - reported mainly in elderly patients or those with renal impairment, particularly at high doses.
• Thrombotic thrombocytopenic purpura / hemolytic uremic syndrome (TTP/HUS): a rare but serious and potentially fatal blood disorder, reported almost exclusively with high-dose Revira in HIV-infected patients and in transplant recipients (e.g., bone marrow or renal transplant); patients on high-dose therapy in these groups should be monitored closely.
• Hypersensitivity reactions, including rash.

Seek medical attention promptly if severe reactions, unusual bruising/bleeding, reduced urination, or significant confusion occur.

Pregnancy: Data from the Revira/Acyclovir pregnancy registries and other observational studies have not shown an increased risk of major birth defects compared with the general population; however, these data are not sufficient to rule out all risk. Revira should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under a physician's advice.

Lactation: Acyclovir (the active metabolite of Revira) is excreted into human breast milk at concentrations higher than corresponding plasma levels. Caution is advised when Revira is administered to a breastfeeding woman; use only if clearly needed and under medical supervision, with the infant monitored for adverse effects.

Before and during treatment with Revira, the following precautions apply:

• Renal function: Revira is cleared renally; dose must be adjusted in patients with renal impairment, and renal function should be monitored, particularly in elderly patients and those on high doses.
• Hydration: maintain adequate fluid intake during treatment, especially at higher doses, to reduce the risk of renal effects.
• TTP/HUS risk: high-dose Revira therapy in severely immunocompromised patients (e.g., advanced HIV infection, transplant recipients) has been associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome; such patients require close monitoring (see Side Effects).
• Neuropsychiatric effects: confusion, agitation, or hallucinations may occur, particularly in the elderly or those with renal impairment; use caution and seek medical review if these occur.
• Complete the full prescribed course and duration for the specific indication being treated, even if symptoms improve, for optimal antiviral effect.
• Revira does not eliminate herpesviruses from the body and does not prevent transmission to others in all circumstances; safer-sex practices should still be used with genital herpes.
• Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Overdose of Revira may cause acute renal failure (due to precipitation of acyclovir in renal tubules) and neurological symptoms such as confusion, agitation, lethargy, seizures, or coma, particularly in elderly patients or those with renal impairment. If an overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center. Hemodialysis may enhance removal of acyclovir from the blood and may be considered by treating physicians in cases of significant overdose associated with renal failure. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Revira requires dose and/or interval adjustment in patients with reduced creatinine clearance across all indications; a physician should individualize dosing based on renal function tests. Adequate hydration is important in this group.

Hepatic impairment: No dose adjustment is generally required in mild-to-moderate hepatic impairment, as conversion of Revira to acyclovir is not substantially reduced, but caution and medical supervision are advised.

Elderly: Older patients are more likely to have reduced renal function and are at higher risk of neurotoxic and nephrotoxic effects; dose adjustment based on renal function and adequate hydration are especially important in this group.

Immunocompromised patients (e.g., HIV infection, transplant recipients): High-dose Revira therapy in these populations carries an increased, though rare, risk of TTP/HUS (see Side Effects and Precautions); close monitoring is advised.

Pediatric use: see Pediatric Uses.

Duration of Revira therapy is indication-specific: 7 days for shingles, 10 days for an initial genital herpes episode, 3 days for a recurrent genital herpes episode, a single day (2 doses) for cold sores, and 5 days for chickenpox in children. Suppressive therapy for recurrent genital herpes may be continued long-term, with periodic reassessment by the prescribing physician (e.g., after 12 months) to determine ongoing need.

Valacyclovir is classified as an antiviral agent, specifically a nucleoside analogue prodrug (of acyclovir) active against herpesviruses (HSV-1, HSV-2, VZV).

Valacyclovir is converted to acyclovir after absorption. Acyclovir is selectively phosphorylated by viral thymidine kinase in HSV/VZV-infected cells to its active triphosphate form, which competitively inhibits viral DNA polymerase and causes chain termination when incorporated into viral DNA, thereby halting viral replication while sparing uninfected host cells.

Category B (former FDA classification)

Revira is approved for use in pediatric patients for specific indications:

• Chickenpox (varicella): approved for immunocompetent children 2 to less than 18 years of age, dosed at 20 mg/kg three times daily (maximum 1 g three times daily) for 5 days; treatment should begin within 24 hours of rash onset.
• Cold sores (herpes labialis): approved for adolescents 12 years of age and older, at the same dose as adults (2 g twice daily for 1 day).

Safety and efficacy for other indications (e.g., genital herpes, herpes zoster) have not been established in children below the approved age ranges; Revira should not be used for these indications in younger children except under specialist advice. Use in neonates and infants under 2 years is not established and generally requires specialist (e.g., pediatric infectious disease) guidance, with acyclovir often preferred in this age group.